Brokerages Anticipate PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Will Post Quarterly Sales of $5.83 Million

Equities research analysts expect that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHASGet Rating) will announce sales of $5.83 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for PhaseBio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $9.17 million. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that PhaseBio Pharmaceuticals will report full year sales of $9.56 million for the current fiscal year, with estimates ranging from $500,000.00 to $18.17 million. For the next fiscal year, analysts expect that the business will post sales of $32.97 million, with estimates ranging from $30.49 million to $35.23 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals (NASDAQ:PHASGet Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.51). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $4.92 million.

Separately, Needham & Company LLC decreased their price objective on PhaseBio Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, March 28th.

PHAS stock opened at $1.29 on Friday. PhaseBio Pharmaceuticals has a 1 year low of $0.96 and a 1 year high of $4.24. The firm has a market capitalization of $62.81 million, a PE ratio of -0.43 and a beta of 2.07. The business has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $2.21.

Several hedge funds have recently modified their holdings of PHAS. Parametric Portfolio Associates LLC purchased a new position in shares of PhaseBio Pharmaceuticals during the second quarter worth about $38,000. Raymond James & Associates acquired a new stake in shares of PhaseBio Pharmaceuticals during the 4th quarter valued at approximately $40,000. IPG Investment Advisors LLC purchased a new position in shares of PhaseBio Pharmaceuticals during the 4th quarter worth approximately $76,000. Squarepoint Ops LLC increased its stake in shares of PhaseBio Pharmaceuticals by 29.8% during the 3rd quarter. Squarepoint Ops LLC now owns 27,083 shares of the company’s stock worth $84,000 after purchasing an additional 6,216 shares in the last quarter. Finally, Pura Vida Investments LLC purchased a new position in shares of PhaseBio Pharmaceuticals during the 3rd quarter worth approximately $87,000. 62.38% of the stock is currently owned by institutional investors.

About PhaseBio Pharmaceuticals (Get Rating)

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure.

Featured Stories

Get a free copy of the Zacks research report on PhaseBio Pharmaceuticals (PHAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.